A pan-cancer transcriptome analysis identifies replication fork and innate immunity genes as modifiers of response to the CHK1 inhibitor prexasertib.
Blosser WD, Dempsey JA, McNulty AM, Rao X, Ebert PJ, Lowery CD, Iversen PW, Webster YW, Donoho GP, Gong X, Merzoug FF, Buchanan S, Boehnke K, Yu C, You XT, Beckmann RP, Wu W, McNeely SC, Lin AB, Martinez R.
Blosser WD, et al. Among authors: mcneely sc.
Oncotarget. 2020 Jan 21;11(3):216-236. doi: 10.18632/oncotarget.27400. eCollection 2020 Jan 21.
Oncotarget. 2020.
PMID: 32076484
Free PMC article.